Biomarker ID | 1426 |
PMID | 24803095 |
Year | 2014 |
Biomarker | PCA3 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Urine |
Subjects | Humans |
Regulation | Upregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: Proteins Involved in Prostate Cancer |
Experiment | Negative Vs Positive Biopsy for PCa |
Type of Biomarker | Diagnostic |
Cohort | 122 patients who underwent pro tate biopsy because of PSA serum levels higher than 4.0 μg/L (93 with positive and 29 with negative biopsy) |
Senstivity | 92.5% |
Specificity | 41.4% |
AUC | All Patients: 0.804; tPSA 4–10 μg/L: 0.793; tPSA 10.1–20 μg/L: 0.821; |
Accuracy | NA |
Level Of Significance | p<0.0001 |
Method Used | RT-PCR |
Clinical | No |
Remarks | The PCA3 score (the measurement of PCA3 mRNA normalized by PSA mRNA). The PCA3 score was calculated as 1/(ctPCA3/ctPSA) |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |